FDA has approved the first generic version of Xofluza (baloxavir marboxil) tablets from Norwich Pharmaceuticals, expanding affordable single‑dose treatment and prophylaxis options for seasonal influenza in patients aged 5 years and older.
Written By: Nikita Jha, BPharm
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) has approved the first generic version of Xofluza (baloxavir marboxil) tablets, providing a more affordable treatment and prevention option for seasonal influenza. Norwich Pharmaceuticals, Inc. received approval for the generic product, which is indicated for patients aged 5 years and older.
FDA Approval and Indications
The approval covers two key uses: treatment of acute uncomplicated influenza in patients who have experienced symptoms for no longer than 48 hours, and post‑exposure prophylaxis following contact with an individual infected with influenza. The generic product, available in 20 mg and 40 mg tablet strengths, is expected to become available in time for the 2026‑2027 influenza season.
Influenza remains a major public health challenge in the United States, causing millions of illnesses, hundreds of thousands of hospitalizations, and thousands of deaths each year. Rapid treatment is particularly important for individuals at higher risk of influenza‑related complications, including older adults, young children, pregnant women, and people with chronic medical conditions.
Mechanism of Action
Baloxavir marboxil is an antiviral medicine that works differently from neuraminidase inhibitors such as oseltamivir. It inhibits the influenza virus cap‑dependent endonuclease, an enzyme required for viral replication. By blocking this step early in the viral life cycle, the drug helps limit viral multiplication and shorten the course of infection when administered promptly after symptom onset.
Clinical evidence from pivotal trials such as CAPSTONE‑1 and CAPSTONE‑2 demonstrated reduced symptom duration and viral shedding, supporting its original FDA approval.
One of the distinguishing features of baloxavir marboxil is its single‑dose oral administration. Unlike many influenza antivirals that require multiple doses over several days, baloxavir is given as a one‑time treatment, which may improve treatment adherence and simplify influenza management.
Safety and Labeling
According to the FDA, generic baloxavir marboxil tablets can be used in otherwise healthy individuals as well as patients at high risk of developing influenza‑related complications, provided treatment begins within 48 hours of symptom onset. The drug is also approved for post‑exposure prophylaxis in eligible patients following influenza exposure.
The safety profile of generic baloxavir marboxil is consistent with the reference product. The medication is contraindicated in patients with a known history of hypersensitivity to baloxavir marboxil or any of its components.
FDA labeling also includes warnings regarding treatment‑emergent resistance, particularly in younger pediatric populations. The most commonly reported adverse reactions include diarrhea, bronchitis, nausea, sinusitis, and headache. Healthcare professionals are advised to review the full prescribing information for detailed dosing recommendations, precautions, and safety guidance.
Public Health and Market Impact
The agency noted that increasing access to generic medicines remains a key public health priority. Dr. Iilun Murphy, Director of the Office of Generic Drugs within FDA’s Center for Drug Evaluation and Research, stated that broader availability of generic medicines can improve patient access while supporting ease of treatment administration. With generic competition expected to improve affordability, broader access to single‑dose antiviral therapy could help strengthen seasonal influenza management and prevention efforts in the years ahead.
What This Means for Patients
The approval of the first generic version of baloxavir marboxil may improve access to a convenient, single-dose treatment and prevention option for influenza. Generic competition often lowers treatment costs, which can help more patients obtain antiviral therapy when it is needed most.
For eligible patients aged 5 years and older, baloxavir offers the advantage of one-time oral dosing, eliminating the need for multiple days of treatment required with some other flu medications. When taken within 48 hours of symptom onset, the antiviral can help reduce the duration of illness and limit viral replication. The availability of a lower-cost generic option ahead of the 2026-2027 flu season could make timely influenza treatment and post-exposure prevention more accessible, particularly for individuals at higher risk of flu-related complications.
Reference
FDA Approves First Single-Dose Generic Treatment for Influenza | FDA
About the Writer
Nikita Jha, BPharm (LinkedIn) a pharmacy graduate specializing in medical writing, with a strong ability to interpret complex medical and regulatory information and translate it into clear, accurate, and evidence-based healthcare content. Known for her attention to detail and precision, she focuses on delivering high-quality scientific communication that supports drug safety and informed decision-making.
